



Ref: Syn/CS/SE/PR/2020-21/April/09

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India

T +91 80 6775 8000

F +91 80 6775 8808

CIN: L85110KA1993PLC01493

www.syngeneintl.com

April 27, 2020

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Press Release

Please find enclosed the press release titled “Syngene International opens COVID-19 RT-PCR testing centre to support Bengaluru hospitals”.

The press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

PRIYADARSHINI
MAHAPATRA
Date: 2020.04.27
21:33:18 +05'30'

Priyadarshini Mahapatra

Company Secretary and Compliance Officer

Press Release

Syngene International opens COVID-19 RT-PCR testing centre to support Bengaluru hospitals

Bengaluru, April 27, 2020:

Syngene International Ltd., a global research and development services company, today announced the opening of a COVID-19 testing laboratory at its Bengaluru site. In less than six weeks, the company used its expertise in clinical trial management, human clinical sample testing procedures, molecular biology and viral testing to gain the additional approvals, including ICMR approval, necessary to open the facility to support hospitals in the city.

Commenting on the development, **Dr Mahesh Bhalgat, Chief Operating Officer, Syngene International Ltd., said,** *“As India battles the COVID-19 pandemic, we are proud to contribute our scientific expertise and resources in supporting the nation in this hour of need. Our COVID-19 testing laboratory, using RT-PCR technology, will work with local hospitals to expand the testing capacity in Bengaluru and help reduce the spread of the virus in the community. The laboratory will be scaling up to operate round-the-clock sample processing and all tests will be offered free of charge.”*

Syngene has repurposed one of its laboratories to conduct the RT-PCR tests. A dedicated team of scientists has been trained to perform these tests as per the guidelines prescribed by national and global regulatory authorities. Necessary processes have been established for safe handling of the samples and testing kits have been sourced and validated.

With the broad range of scientific expertise in relevant disciplines that Syngene offers, it is also working to supply reagents, primers and probes for COVID-19 diagnostic testing to clients, as well as working on research projects related to vaccine development which could represent a longer-term solution for fighting the coronavirus pandemic.

Press Release

RT-PCR or Real Time PCR is an advanced technology which is used to detect the expression level of the relevant RNA fragment. It monitors the amplification of a targeted oligonucleotide sequence in real-time and uses fluorescent dyes to detect the presence of the virus.

At present, there are 277 government laboratories approved and supported by the ICMR and 16 private labs for testing Coronavirus including 6 in Bangalore.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation-focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene's clientele includes world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4200-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed up time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.

Contact details

Investor Contact	Media Contact
Sapna Hb P: +918067753902 M: +917899911289 Fax: +91 80 2852 3423 E: Sapna.Hb@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com